» Articles » PMID: 7478525

Characterization of Essential Domains for the Functionality of the MHBst Transcriptional Activator and Identification of a Minimal MHBst Activator

Overview
Journal Oncogene
Date 1995 Nov 16
PMID 7478525
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Integrated hepatitis B virus DNA derived from hepatocellular carcinomas can express, in one third of the cases investigated so far, a transcriptional activator encoded from 3' terminal truncated surface (preS/S) genes resulting in a C-terminally truncated middle surface protein (MHBst). Since MHBst, in contrast to the secreted MHBs, is retained in the secretory pathway at the ER, the question as to whether the retention generates the transcriptional activator function was investigated. Through fusion of MHBs to the ER-retention signal KDEL, it was shown that the intracellular retention does not generate the transcriptional activator function. Tryptic digestions of microsomal vesicles revealed that the amino terminal domain of MHBst directs into the cytoplasmic compartment, whereas in MHBs this domain directs into the lumen of the ER. This structural difference appears to be why transcriptional activator function arises. Through deletion analysis it was shown that non-membrane-associated MHBst proteins are also functional activators. Nonmembrane associated MHBst proteins represent a second class of MHBst proteins. These MHBst-proteins are homogenously distributed all over the cell and show no difference in functionality as compared to the membrane-associated MHBst proteins. MHBst53 (truncated at aa53) was shown to be a minimal activator of this class. Both classes of MHBst proteins were found to form dimers; an which is involved in mediating the dimerization. The integrity of this domain was also revealed to be a prerequisite for the functionality of the activator, suggesting a linkage between dimerization and functionality.

Citing Articles

[Hepatitis B and C: mechanisms of virus-induced liver pathogenesis and tumorigenesis].

Glitscher M, Hildt E, Bender D Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022; 65(2):228-237.

PMID: 35015106 PMC: 8813796. DOI: 10.1007/s00103-021-03482-y.


Intracellular Trafficking of HBV Particles.

Jiang B, Hildt E Cells. 2020; 9(9).

PMID: 32887393 PMC: 7563130. DOI: 10.3390/cells9092023.


Effect of Hepatitis Viruses on the Nrf2/Keap1-Signaling Pathway and Its Impact on Viral Replication and Pathogenesis.

Bender D, Hildt E Int J Mol Sci. 2019; 20(18).

PMID: 31546975 PMC: 6769940. DOI: 10.3390/ijms20184659.


Hepatitis B virus pre-S/S variants in liver diseases.

Chen B World J Gastroenterol. 2018; 24(14):1507-1520.

PMID: 29662289 PMC: 5897855. DOI: 10.3748/wjg.v24.i14.1507.


HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma.

Liu P, Zhang H, Liang X, Ma H, Luan F, Wang B Oncotarget. 2015; 6(30):29048-59.

PMID: 26315112 PMC: 4745710. DOI: 10.18632/oncotarget.4804.